Clinical trial · Interventional
Tobacco, Alcohol and Cancerization of the Oral Mucosa (TACO)
Clinical-biological, Prospective, Monocentric Cohort Study to Describe Somatic Mutations in Healthy Oral Mucosa From Patients With Oral Squamous Cell Carcinoma (OSCC)
NCT06425146CI-TRIAL-00080083TACOunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this project is to describe somatic mutations of healthy oral mucosa from patients with oral squamous cell carcinoma (OSCC).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Oral Squamous Cell Carcinomas | Oral Cavity Squamous Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sampling | Procedure | — | UNRESOLVED |
| Cytobrush sample | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Clinical-biological cohort
- description
- A clinical-biological cohort of 30 patients with epidermoid carcinomas of the oral cavity. Blood sample and cytobrush sample at inclusion and before anti-cancer treatment.
- interventionNames
- Procedure: Cytobrush sample
- Procedure: Blood sampling
Primary outcomes (1)
- measure
- Identify somatic mutations of the driver genes from healthy oral mucosa from patients with epidermoid carcinomas of the upper aerodigestive tract
- timeFrame
- 1 year
- description
- Identified mutations described by type and number
Secondary outcomes (2)
- measure
- Correlation between tobacco consumption and the total number of somatic mutations detected in the healthy oral mucosa in patients with OSCC
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * I1. Male or female aged 18 years or older at the date of signature of the informed consent to participate. * I2. Patient with histological diagnosis of epidermoid carcinomas of the oral cavity NB: All grades are eligible. * I3. Patient naive of any systemic anti-cancer treatment (radio- or chemotherapy). * I4. Patient able to understand, sign and date informed consent before the start of any study protocol procedure. * I5. Patient affiliated or covered by a medical insurance Exclusion Criteria: * E1. Patients at high risk of bleeding, such as those on anticoagulant or antiplatelet aggregant treatment, with clotting disorders or a history of severe bleeding in the two weeks prior to inclusion. * E2. Patient with lesions of all types on the mucosa of the cheek located on the opposite side of the area affected by an epidermoid carcinoma of the oral cavity which prevents painless removal of the healthy mucosa. * E3. Patient who had surgery for their epidermoid carcinoma of the oral cavity more than 6 months ago. * E4. Patient who uses cannabis. * E5. Patient with another active tumor or HPV-positive tumors. * E6. Patient under guardianship or curatorship or placed under the protection of justice. * E7. Pregnant and/or nursing patient.
References
Publications (0)
Data not yet available
No reference posted for this study.